Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis

Clinical and Experimental Allergy

Volumn 41, Issue 8, 2011, Pages 1098-1107

  Tasic, T ^a   Baumer W ^b   Schmiedl, A ^a   Schwichtenhovel F ^a   Pabst, R ^a   Raap, U ^a   von Horsten S ^a,c   Stephan, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CD26; Contact hypersensitivity; Rats

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; DIPEPTIDYL PEPTIDASE IV; TOLUENE DIISOCYANATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SKIN BIOPSY; SKIN INFLAMMATION; TH1 CELL; TH2 CELL; UPREGULATION; WILD TYPE;

ANIMALS; ANIMALS, CONGENIC; BIOPSY; CELLS, CULTURED; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DIPEPTIDYL PEPTIDASE 4; GENE EXPRESSION REGULATION; HUMANS; RATS; SKIN TESTS; TH1 CELLS;

EID: 79960434159     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03778.x     Document Type: Article

References (43)

1. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85:9-24.
2. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999; 20:367-75.
3. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 2008; 29:295-301.
4. Forssmann U, Stoetzer C, Stephan M et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol 2008; 181:1120-7.
5. Proost P, De Meester I, Schols D et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998; 273:7222-7.
6. Shingu K, Helfritz A, Zielinska-Skowronek M et al. CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. Cancer Immunol Immunother 2003; 52:546-54.
7. Ohnuma K, Inoue H, Uchiyama M et al. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 2006; 16:3-13.
8. van Lingen RG, van de Kerkhof PC, Seyger MM et al. CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol 2008; 158:1264-72.
9. Kruschinski C, Skripuletz T, Bedoui S et al. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 2005; 139:17-24.
10. Schade J, Schmiedl A, Stephan M, Pabst R, von Horsten S. Transferred T cells preferentially adhere in the BALT of CD26-deficient recipient lungs during asthma. Immunobiology 2010; 215:321-31.
11. Skripuletz T, Schmiedl A, Schade J et al. Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1564-71.
12. Lun SW, Wong CK, Ko FW, Hui DS, Lam CW. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. J Clin Immunol 2007; 27:430-7.
13. Meagher LJ, Wines NY, Cooper AJ Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australasian Journal of Dermatology 2002; 43:247-54.
14. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361:151-60.
15. Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol 2007; 25:547-54.
16. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-94.
17. Green BD, Flatt PR, Bailey CJ. Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes. Expert Opin Emerg Drugs 2006; 11:525-39.
18. Schade J, Stephan M, Schmiedl A et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 2008; 56:147-55.
19. Frerker N, Raber K, Bode F et al. Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. Clin Chem Lab Med 2009; 47:275-87.
20. Rehbinder C, Baneux P, Forbes D et al. FELASA recommendations for the health monitoring of mouse, rat, hamster, gerbil, guinea pig and rabbit experimental units. Report of the Federation of European Laboratory Animal Science Associations (FELASA) Working Group on Animal Health accepted by the FELASA Board of Management, November 1995. Lab Anim 1996; 30:193-208.
21. Klemann C, Schade J, Pabst R et al. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clin Exp Immunol 2009; 155:357-65.
22. Baumer W, Seegers U, Braun M, Tschernig T, Kietzmann M. TARC and RANTES, but not CTACK, are induced in two models of allergic contact dermatitis. Effects of cilomilast and diflorasone diacetate on T-cell-attracting chemokines. Br J Dermatol 2004; 151:823-30.
23. Baumer W, Gorr G, Hoppmann J, Ehinger AM, Rundfeldt C, Kietzmann M. AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol 2003; 55:1107-14.
24. Wrann CD, Ehmer U, Lautenbach A, Kuhlmann S, Nave H. Obesity and NK cells affect the expression of the long form of the leptin receptor Ob-Rb in liver of F344 rats. Exp Toxicol Pathol 2010; 62:1-8.
25. Novelli M, Savoia P, Fierro MT, Verrone A, Quaglino P, Bernengo MG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol 1996; 134:1052-6.
26. Ansorge S, Bank U, Heimburg A et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009; 47:253-61.
27. Seitzer U, Scheel-Toellner D, Mattern T, Haas H, Flad HD, Gerdes J. Staining pattern of seven monoclonal anti-CD26 antibodies in leprosy: implications for the use of CD26 as a surrogate marker of a human Th1-like reaction. Virchows Arch 1998; 432:343-7.
28. Vlahovic P, Avramovic V, Stankovic M, Savic S, Todorovic M. Elevated serum dipeptidyl peptidase IV activity in patients with chronic tonsillitis. Ann Clin Biochem 2007; 44:70-4.
29. Tanaka K, Takeoka A, Nishimura F, Hanada S. Contact sensitivity induced in mice by methylene bisphenyl diisocyanate. Contact Dermat 1987; 17:199-204.
30. Willheim M, Ebner C, Baier K et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol 1997; 100:348-55.
31. Hoshimoto K, Ohta N, Ohkura T, Inaba N. Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance? Gynecol Obstet Invest 2000; 50:260-3.
32. Boonacker EP, Wierenga EA, Smits HH, Van Noorden CJ. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 2002; 50:1169-77.
33. Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. Curr Allergy Asthma Rep 2004; 4:276-84.
34. Giustizieri ML, Mascia F, Frezzolini A et al. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 2001; 107:871-7.
35. Loetscher P, Pellegrino A, Gong JH et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001; 276:2986-91.
36. Dearman RJ, Basketter DA, Kimber I. Characterization of chemical allergens as a function of divergent cytokine secretion profiles induced in mice. Toxicol Appl Pharmacol 1996; 138:308-16.
37. Hopkins JE, Naisbitt DJ, Kitteringham NR, Dearman RJ, Kimber I, Park BK. Selective haptenation of cellular or extracellular protein by chemical allergens: association with cytokine polarization. Chem Res Toxicol 2005; 18:375-81.
38. Proost P, Schutyser E, Menten P et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98:3554-61.
39. Steinbrecher A, Reinhold D, Quigley L et al. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol 2001; 166:2041-8.
40. Williams YN, Baba H, Hayashi S et al. Dipeptidyl peptidase IV on activated T cells as a target molecule for therapy of rheumatoid arthritis. Clin Exp Immunol 2003; 131:68-74.
41. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008:CD006739.
42. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194-206.
43. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20:224-35.